Can we think of competing-event as another form of non-event in terms of utility?
|
|
0
|
75
|
April 21, 2024
|
Overall survival vs disease-free survival and other surrogate endpoints
|
|
5
|
6497
|
April 11, 2024
|
Use of percentage change in clinical trials
|
|
16
|
606
|
April 8, 2024
|
Individual response
|
|
236
|
34374
|
March 24, 2024
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
345
|
February 23, 2024
|
Evaluating seizures in open-label studies
|
|
5
|
241
|
February 20, 2024
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
34
|
2848
|
February 16, 2024
|
Does subtracting/or not, the mean-rank in Wilcoxon-Mann-Whitney make any difference?
|
|
4
|
280
|
February 1, 2024
|
Ranked analysis of ANCOVA
|
|
7
|
594
|
January 21, 2024
|
AUC of each subgroup is smaller than overall AUC
|
|
7
|
3935
|
November 13, 2023
|
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times
|
|
2
|
513
|
October 3, 2023
|
About the interpret category
|
|
1
|
3010
|
October 3, 2023
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
579
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
682
|
August 29, 2023
|
Design of Experiments in Economics vs Medicine: a Decision Theory POV
|
|
6
|
1536
|
July 27, 2023
|
Inferences from summary data - without seeing the data for a Cox PH model, do chi square tests tell us anything?
|
|
5
|
259
|
July 24, 2023
|
Case-control study with and corresponding subgroup
|
|
2
|
567
|
July 20, 2023
|
Impact of Model Intercepts on Ordinal Logistic Regression Outcome
|
|
7
|
636
|
June 22, 2023
|
P values and small sample size
|
|
6
|
723
|
June 20, 2023
|
Minimum PPV/NPV values to reach positive net benefit and net benefit avoided
|
|
10
|
1251
|
June 12, 2023
|
Outlier detection
|
|
3
|
1027
|
May 11, 2023
|
HR really close to 1 but significant - how to interpret and report?
|
|
9
|
1212
|
April 25, 2023
|
FDA "Bad Habits"
|
|
7
|
1891
|
March 4, 2023
|
Advice regarding a Directed Acyclic Graph and further analysis Plan
|
|
7
|
1106
|
January 22, 2023
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
23
|
2559
|
January 4, 2023
|
R package to present summary results from many different mixed effects models
|
|
3
|
873
|
December 28, 2022
|
Interpretation of subject-specific effect in a cross-over study
|
|
5
|
3436
|
November 28, 2022
|
Generalized Additive Models with R gam
|
|
1
|
1502
|
November 22, 2022
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
2209
|
November 21, 2022
|
Categorization of continuous outcome and odds ratio
|
|
2
|
756
|
November 8, 2022
|